Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share transactions executed on July 23 and July 24, 2014, involving Sir Andrew Witty, Lady Caroline Witty, and connected persons.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the sale, repurchase, and transfer of ordinary shares into Individual Savings Accounts (ISAs).
Important Facts for Investors
- Transaction Dates: Sales occurred on July 23, 2014; repurchases and ISA transfers occurred on July 24, 2014.
- Parties Involved: Sir Andrew Witty (Director), Lady Caroline Witty, and connected persons.
- Share Activity: Each party sold 215 Ordinary Shares and repurchased 211 Ordinary Shares.
- Transaction Prices: Sales were executed at approximately 1462.0750p per share; repurchases ranged between 1462.4250p and 1462.9250p per share.
- Document Scope: This filing does not contain quarterly or annual financial results.